SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $629,911,888 |
| Positions | 35 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| LB PHARMACEUTICALS INC | LBRX | COM SHS | $49,429,679 | 1,523,022 |
| NURIX THERAPEUTICS INC | NRIX | COM | $38,166,318 | 1,573,220 |
| IMMUNOCORE HLDGS PLC | IMCR | ADS | $33,757,680 | 1,063,234 |
| FIRST TRACKS BIOTHERAPEUTICS | TRAX | ORD SHS | $30,461,680 | 1,514,000 |
| 4D MOLECULAR THERAPEUTICS IN | FDMT | COM | $29,631,296 | 2,227,917 |
| BIOMARIN PHARMACEUTICAL INC | BMRN | COM | $29,296,640 | 512,000 |
| DESIGN THERAPEUTICS INC | DSGN | COM | $28,958,550 | 2,001,282 |
| XENON PHARMACEUTICALS INC | XENE | COM | $26,558,400 | 440,000 |
| MIRUM PHARMACEUTICALS INC | MIRM | COM | $26,143,136 | 223,312 |
| INSMED INC | INSM | COM PAR $.01 | $24,557,891 | 230,331 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.